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ABSTRACT

Taurolidine is an experimental anti-bacterial and anti-endotoxic compound whose clinical
utility as an anti-tumor agent is being investigated in human clinical trials. Taurolidine in
aqeous solution exists in equilibrium with taurultam.

Taurultam is subsequently

transformed to taurinamide. The pharmacokinetic profiles of these metabolites are not
well established. In this study, eighteen healthy volunteers were administered 5.0 g of
taurolidine in 250 mL of 5% polyvinylpyrrolidone in water over either 2, 1, or 0.5 hour
by intravenous infusion in a parallel group design. All subjects noted discomfort at the
infusion site, though there were no serious adverse events. Tmax generally occurred at the
end of infusion for taurinamide while that of taurultam was reached before completion of
infusion. The taurolidine metabolite taurultam demonstrated a shorter half-life and lower
systemic exposure than taurinamide. Shortening of infusion duration increased the Cmax
and AUC of taurultam.

Changes in infusion rate did not substantially change the

pharmacokinetic parameters of taurinamide.
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INTRODUCTION

Taurolidine [TRD] is a small dimeric molecule with bactericidal properties against a
broad spectrum of bacteria ranging from anaerobic to aerobic species.1, 2, 3 Tauroldine’s
mechanism of action as an antibiotic agent is associated with a chemical reaction between
the active TRD metabolites, taurultam [TRT] and taurinamide [TRM] with the structures
of bacterial wall.3,

6

In addition, TRD exhibits the ability to neutralize bacterial

endotoxins, exotoxins and lipopolysaccharides.7,

8, 9

The most widespread clinical

application of TRD at present is as a catheter lock solution to reduce the incidence of
vascular access-associated blood stream infections.

Other clinical applications have

included peritoneal lavage for prophylaxis against post-operational bacterial infections in
patients with established peritonitis following elective colorectal surgeries, and as an antiendotoxic agent in patients with systemic inflammatory response syndrome.2, 3, 10

TRD has also been investigated extensively as an experimental anti-neoplastic agent in in
vitro and in vivo studies.11, 12, 13, 14 It appears to have a direct effect on various tumor cell
lines with a consecutive inhibition in cell growth.12,

15

Preclinical investigations have

suggested activity against colon, ovarian, and prostate cancer, as well as melanoma, and
mesothelioma.

Of significance, intra-peritoneal and systemic application of TRD

resulted in a reduction of intra- and extra-peritoneal metastases in rodent models,
suggesting utility as a chemopreventive agent against metastases.11,

16

Indeed,

prophylactic, intra-operative peritoneal lavage with TRD for prevention of metastatic
diseases has been successfully applied, while intravenous administration of the agent as
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the primary treatment of poorly managed malignancies has been currently investigated in
clinical trials.17, 18

Despite administration to over 13,000 patients, the pharmacokinetics of TRD metabolites
has not been comprehensively characterized in humans.

TRD in aqueous solution

undergoes rapid conversion to TRT, with smaller amounts of hydroxymethyltaurultam.
TRT is subsequently converted to TRM [Figure 1].19,

20

Because of these metabolic

characteristics, the TRD metabolites are more important pharmacokinetic markers than
the parent compound in studying its pharmacodynamic properties including antibacterial
and anti-neoplastic repertoire. In this study, the pharmacokinetics of TRD metabolites
was investigated in healthy volunteers following intravenous administration of TRD
solution.

METHODS

Subjects
Healthy male or female subjects between the ages of 18 and 45 years, between 45 and
100 kg and within 20% of ideal body weight range for body frame, were eligible to
participate in the present study. The use of prescription medications and tobacco were
exclusion criteria. The study was approved by the institutional review board of Thomas
Jefferson University. All subjects gave written informed consent to participate prior to
undergoing any study-related procedures.
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Study Design
This was an open labeled, three-arm, single dose, parallel study that compared the
pharmacokinetics and safety of [1] 5.0 gram [g] taurolidine intravenous infusion over 2
hours [h], [2] 5.0 g taurolidine intravenous infusion over 1 h and [3] 5.0 g taurolidine
intravenous infusion over 0.5 h. Taurolidine was prepared as a 2% solution in 250 ml of
water and 5% polyvinylpyrrolidone [Kollidon® 17, BASF].

Healthy volunteers

underwent a screening visit within three weeks of drug administration. Each subject was
admitted to the Clinical Pharmacology Research Unit of Thomas Jefferson University
Hospital the day before each treatment. Following an overnight fast, they received one of
the three treatments. Clinical laboratory tests, electrocardiogram, and vital signs were
performed at baseline and at specified intervals post dose. Twenty-four hours after each
treatment, subjects were discharged from the unit.

Collection and determination of analyte concentrations
Blood was drawn for TRT and TRM pharmacokinetics predose, and at 5, 15, 30, 45 min,
and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18 and 24 hours postdose. Time zero was the beginning
of intravenous infusion. Blood samples were collected in sodium heparin-containing
tubes, and immediately [within 40 seconds] mixed with the derivatizing agent 9fluorenylmethyl-chlorformate [FMOC-CI] in an acetonitrile and pseudoephedrine
processing solution.

Samples were incubated at room temperature between 30-45

minutes, followed by freezing at -200C.

Analysis was performed by Kansas City

Analytical Services [Shawnee, KS] using a validated high performance liquid
chromatography [HPLC] method.

In addition to the pre-column derivatization, the
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method consisted of liquid-liquid extraction, gradient HPLC separation, and fluorescence
detection using a 260 nm excitation/340 nm emission cut-off filter. The analytic range
for TRT was 20 to 1000 µM and 20 to 900 µM for TRM. At the time of analysis,
samples were thawed, combined with additional derivatizing reagent FMOC-Cl, and
respective TRT and TRM internal standards. The samples were allowed to react for 10
min, quenched with the addition of taurine, and extracted into an organic solvent. The
extracts were reconstituted in mobile phase and subjected to reverse phase HPLC using a
5 µ ODS column. The analytes were detected using fluorescence detection and system
calibration was accomplished by weighted linear least-square regression of the weightnormalized peak height ratio [analyte/internal standard] vs. the nominal concentration of
analyte.

During validation, the correlation coefficient [r] was ≥0.995 for TRT and

≥0.997 for TRM, respectively. The precision for this assay was 1.3 to 15.95% CV for
TRT and 2.3 to 8.5% for TRM, respectively, while accuracy [% of recovery] was 94.9 to
116.3% for TRT and 102.1 to 114.6% for TRM.

Pharmacokinetic Analysis
The apparent clearance [Cl] and volume of distribution [Vd] of TRD metabolites, TRT
and TRM, following intravenous infusion of TRD, along with the terminal elimination
rate constant [λz], and corresponding half-life [t1/2], maximum concentration [Cmax], time
to maximum concentration [Tmax], observed area under the curve [AUC0-24] and area
under the curve extrapolated to infinity [AUC0-∞], were estimated based on whole blood
concentration [µg/mL] versus time [h] data using non-compartmental methods
[WinNonlin 5.01 software; Pharsight, Mountain View, CA].
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RESULTS

Demographics
Eighteen healthy volunteers [16 males and 2 females] with a mean age of 30.7 [range 21
to 42], participated in the study. Ten subjects were black, 6 white, one Hispanic and one
subject was self-described as mixed race. Detailed demographic data is summarized in
Table 1. All subjects completed the study.

Pharmacokinetics
The present study compared the pharmacokinetics of TRD metabolites over 3 different
durations of intravenous infusion with parent compound TRD [Tables 2, 3; Figure 2].
Data from the subject in the one hour infusion group who had his infusion rate decreased
on account of infusional burning was not included in PK analysis. Estimated clearance
and volume of distribution were calculated using the assumption of a 5 gm dose of parent
compound. The mean clearance (L/hr) was 124.6 (SD 35.7) for TRT and 16.5 (SD 3.2)
for TRM. The mean volume of distribution (L) was 252.9 (SD 132.9) for TRT and 155.1
(SD 32.5) for TRM. Each metabolite is proportional to parent on a molar basis but
involves the liberation of water, so the clearance and volume of distribution presented are
likely overestimates of actual values. The AUC and Cmax of TRT increased, and Cl
decreased with decreasing infusion time, suggesting a saturable elimination process.
TRM lacked such changes and with the exception of Tmax, pharmacokinetic parameters
were comparable across different durations of infusion. Due to the limited number of
time points during the first hour after the initiation of intravenous infusion, Tmax values
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should be considered estimates. Maximum concentrations were reached sooner for TRT
in the order of 0.5 hr-infusion < 1 hr-infusion < 2 hr-infusion (p = 0.0017). The Tmax for
TRM occurred essentially at the end of infusion while that of TRT appeared generally to
be achieved before completing the infusion (p < 0.05).

Safety
Safety data on all subjects in the trial is reported. There were no serious adverse effects
associated with the administration of taurolidine infusions. No hypotension was noted
during drug infusion. All subjects noted burning at the infusion site. Five were graded as
mild, twelve as moderate, and one subject in the one hour infusion rate group had severe
buring that required a decrease in the rate of infusion. Seven subjects also described a
numbness or soreness in the infusion arm or shoulder. Four episodes were ranked as mild
and three as moderate. Infusion-related symptoms began within one minute of onset and
generally ceased at the end of infusion. Four subjects had mild erythematous streaking at
the site of the IV, which also resolved quickly after the end of infusion. Five subjects had
facial flushing, of which four were mild and one was moderate. Four of the flushing
episodes took place in the 0.5 hr-infusion group and one in the 1 hr group. Other adverse
events included single occurrences of headache, epistaxis, and nausea. There were no
clinically significant abnormalities in vital signs, electrocardiograms, and clinical
laboratory tests except one subject with a single elevated prothrombin time value felt to
be possibly related to study drug.
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DISCUSSION

TRD was synthesized in 1970s and was originally used as an antibiotic in the
prophylactic treatment of intraperitoneal bacterial infections in patients with established
peritonitis.1, 2, 3 The utility of taurolidine as an anti-tumor agent has been investigated
extensively recently.17

Although intra-operative peritoneal lavage of TRD for

prophylactic therapies either as an antibiotic or as an anti-tumor agent against metastatic
diseases has been administered clinically, the pharmacokinetics of TRD metabolites after
intravenous administration was not well established. Pharmacokinetic characterization of
taurolidine metabolites had been hampered by the rapid in vivo conversion of TRT to
TRM. Key to the present investigation was the development of a sensitive assay and
careful attention to derivatizing samples immediately after collection.

Previous analytical studies on animal specimens revealed that TRD exists in equilibrium
with TRT, which further reversibly converts to TRM and other degradation products
[Figure 1].19, 20 In a clinical investigation, Erb et al19 reported a biphasic elimination of
TRT in a model-based analysis after IV administration of 1 gram over one hour in six
subjects using a different analytic method. Beta t1/2 was reported as 2.2 h and Vd was 162
± 93 L, which is comparable to the findings reported here [Table 2]. In the present study,
intravenous infusion of 5.0 g of taurolidine resulted in a smaller AUC for TRT than for
TRM and, conversely, a larger Cl for the former than for the latter [Table 2 and 3]. These
findings demonstrate that TRT is an unstable and short-lived metabolite.

Prior

investigations revealed that the antibiotic action of TRD appeared to be related to action
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of active metabolites methylol TRT and methylol TRM [Figure 1] on bacterial cell
walls,2,

21

while the antitumor activities were likely due to its proapoptotic and

antiangiogenic effects on tumor cells.17,

18

The present study did not include

pharmacodynamic measures to define mechanisms of action of each metabolite.

TRD not only acts as an antibacterial agent to suppress infection but also prevents the
growth and spread of tumor cells. In oncology patients, intravenous infusions were
reported of up to 20 g/day (1,000 ml of 2% TRD), which were ~4 times more than that
examined in the present study, and few clinically relevant drug adverse effects were
observed.15,

17, 22

Anti-tumor activity has been noted preclinically at micromolar

concentrations in many tumor cell lines.18 These concentrations were demonstrated for
both metabolites in the present study. The PK parameters generated in this study will
assist in the rational dose and infusion interval selection in future human clinical trials.

Finally, safety data reported here in healthy adults indicate that local reactions including
burning at the infusion site, numbness or soreness of the infusion arm and erythematous
streaking at the IV site were the most common adverse effects associated with
intravenous TRD administration.

Systemic clinically relevant drug toxicities were

minimal in this study, in accordance with the other prior clinical investigations related to
the low toxicity of this agent.17

In summary, there was no serious adverse events occurred in intravenous administrations
of 5 g TRD 2% solution in healthy subjects. Local irritation at infusion sites was
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observed although all subjects completed the infusion.

The TRD metabolite TRT

demonstrated a shorter half-life and systemic exposure than TRM.

Shortening of

infusion duration increased the Cmax and AUC of TRT relative to that of TRM.
Characterization of metabolite pharmacokinetics will assist in the further clinical
development of TRD.
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Table 1: Demographic characteristics of research subjects

Group
n
Age (yrs)
Weight (kg)
Height (cm)
Gender (M:F)

2-h infusion
6
27.7 ± 2.3
60.3 ± 7.9
167.9 ± 7.7
5:1

1-h infusion
6
30.3 ± 8.0
87.7 ± 14.8
167.9 ± 7.7
5:1

All data are presented as mean ± S.D.

.
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0.5-h infusion
6
31.0 ± 7.3
82.5 ± 16.9
179.3 ± 10.5
6:0

Table 2: Mean Pharmacokinetic Parameters of Taurultam
Duration of
infusion
hr
2
1
0.5
All Groups
* = median

n

6
5
6

AUC(0-24)

AUC(0-ω)

Cmax

hr*ug/mL
hr*ug/mL
ug/mL
34.9 ± 9.6
35.7 ± 9.0
16.0 ± 4.5
37.3 ± 10.1
40.7 ± 11.2
32.0 ± 16.1
44.8 ± 9.8
51.8 ± 10.6
51.4 ± 12.2
38.8 ± 9.8
42.9 ± 11.4
32.0 ± 17.9
All data are presented as mean ± S.D.

half life

Tmax

hr
1.1 ± 0.3
1.2 ± 0.7
2.1 ± 1.1
1.5 ± 0.9

hr
1.50
0.75
0.50
0.50*

Table 3: Mean Pharmacokinetic Parameters of Taurinamide
Duration of
infusion
hr
2
1
0.5
All Groups
* = median .

n

6
5
6

AUC(0-24)

AUC(0-ω)

Cmax

hr*ug/mL
hr*ug/mL
ug/mL
315.4 ± 46.5 356.5 ± 61.1 53.9 ± 10.8
233.9 ± 29.4 269.0 ± 35.3 59.4 ± 19.4
271.7 ± 61.4 310.3 ± 67.2 62.6 ± 16.8
273.4 ± 55.8 312.7 ± 63.2 57.3 ± 15.3
All data are presented as mean ± S.D.
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half life

Tmax

hr
6.9 ± 1.5
6.5 ± 1.4
6.7 ± 1.2
6.7 ± 1.3

hr
2.00
1.00
0.63
1.00*

Figure 1: Metabolic disposition of taurolidine

Figure 2: Concentration time curves for taurultam (TRT) and taurinamide (TRM) following intravenous infusion of
taurolidine

Figure Legend
Figure 2 Time-concentration relationship of the taurolidine metabolites taurultam and taurinamide in three intravenous infusion
groups. Panel (A) 2-, 1- and 0.5-h infusion groups for taurultam (B) 2-, 1- and 0.5-h infusion groups for taurinamide. All data were
presented as mean ± S.D.
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